HIV-2 antigen compositions

Details HIV-2 antigen compositions HIV-2 antigen compositions

2008-03-11

2008-03-11

Parkin, Jeffrey S. (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Virus or component thereof

Reexamination Certificate

active

10180460

ABSTRACT:
The invention relates to a composition comprising at least one antigen, wherein the antigen is a protein or glycoprotein of a HIV-2 virus, wherein the HIV-2 virus has infectious properties with respect to human T4 lymphocytes and the essential morphological or immunological property of at least one of the retroviruses deposited at the CNCM under No. I-502, I-532, I-642, and I-643. It also relates to a process for the production of HIV-2 retrovirus antigens by lysing cells infected with the virus or lysing purified virus and recovering the antigens.

REFERENCES:
patent: 4839288 (1989-06-01), Montagnier et al.
patent: 5051496 (1991-09-01), Alizon et al.
patent: 5055391 (1991-10-01), Montagnier et al.
patent: 5066782 (1991-11-01), Montagnier et al.
patent: 5079342 (1992-01-01), Alizon et al.
patent: 5223423 (1993-06-01), Franchini et al.
patent: 5268265 (1993-12-01), Montagnier et al.
patent: 5306614 (1994-04-01), Alizon et al.
patent: 5670309 (1997-09-01), Norrby et al.
patent: 6037165 (2000-03-01), Montagnier et al.
patent: 6162439 (2000-12-01), Alizon et al.
patent: WO 85/04897 (1985-11-01), None
patent: WO 86/06414 (1986-11-01), None
F. Clavel, et al., “Molecular cloning and polymorphism of the human immune deficiency virus type 2,”Nature, 324:691-695 (1986).
F. Gao, et al., “Genetic Diversity of Human Immunodeficiency Virus Type 2: Evidence for Distinct Sequence Subtypes with Differences in Virus Biology,”Journal of Virology, 68(11):7433-7447 (1994).
M. Goodenow, et al., “HIV-1 Isolates Are Rapidly Evolving Quasispecies: Evidence for Viral Mixtures and Preferred Nucleotide Substitutions,”Journal of Acquired Immune Deficiency Syndromes, 2:344-352 (1989).
M. Guyader, et al., “Genome organization and transactivation of the human immunodeficiency virus type 2,”Nature, 326:662-669 (1987).
J. Hunt, et al., “Discrimination Between HIV-1 and HIV-2-Seropositive Individuals Using Mouse Monoclonal Antibodies Directed to HIV Transmembrane Proteins,”AIDS Research and Human Retroviruses, 6(7):883-898 (1990).
R. Keller, et al., “Amino Acid Changes in the Fourth Conserved Region of Human Immunodeficiency Virus Type 2 Strain HIV-2RODEnvelope Glycoprotein Modulate Fusion,”Journal of Virology, 67(10): 6253-6258 (Oct. 1993).
W. Strongin, “Sensitivity, Specificity, and Predictive Value of Diagnostic Tests: Definitions and Clinical Applications,”Laboratory Diagnosis of Viral Infections, 2ndEd., p. 211-219 (1992).
L. Stryer, “Bacterial Cell Walls,”Biochemistry, Chapter 31, pp. 761-763.
R. Tedder, et al., “Envelope Cross-Reactivity in Western Blot for HIV-1 and HIV-2 May Not Indicate Dual Infection,”The Lancet, 11(8617):927-930 (1988).
L. Chakrabarti, et al., “Sequence of simian immunodeficiency virus from macaque and its relationship to other human and simian retroviruses,”Nature, 328:543-547 (1987).
S. Wain-Hobson, et al., “Nucleotide Sequence of the AIDS Virus, LAV,”Cell, 40:9-17 (1985).
J. Wang, “Detection of antibodies to human T-lymphotropic virus type III by using a synthetic peptide of 21 amino acid residues corresponding to a highly antigenic segment of gp41 envelope protein,”Proc. Natl. Acad. Sci., USA, 83:6159-6163 (1986).

Affiliated with

Also associated with

Rating

HIV-2 antigen compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HIV-2 antigen compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV-2 antigen compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3917453